Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIC: Prevention of Radiation Dermatitis in Breast Cancer
NCT07918989Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mometasone furoate nasal spray, mupirocin and chlorhexidine + cymenol gel in radiation dermatitis (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Rate of acute radiation dermatitis with moist desquamation at 12 months. Started Oct 2026; status: recruiting.
02
Drugs
mometasone furoate nasal spraymupirocinchlorhexidine + cymenol gel
03
Conditions
radiation dermatitis
Beyond the preview
Go deeper on NCT07918989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07918989.